BUSINESSWEEK ONLINE : JUNE 12, 2000 ISSUE
COVER STORY

Genomics among the Giants


While the payoff may be years away, Big Pharma is racing to build its genomics expertise.

GLAXO SMITHKLINE *
SmithKline was early to genomics with its 1993 deal to gain access to Human Genome Sciences data. Glaxo is working to identify genes that make people susceptible to diseases like asthma.

PFIZER INC. **
Pfizer has struck external alliances, including a November, 1999, deal with gene-sequencing company Celera. The two companies will work together to identify drug targets from Celera's massive genomic database.

MERCK & CO.
The company has struck deals with companies such as DNA chipmaker Affymetrix to access new technology. Merck is relying largely on public information and its own gene sleuths to uncover new drug targets.

BRISTOL-MYERS SQUIBB
It has struck more than a dozen alliances in three years. A big player in cancer drugs, Bristol is collecting tumor samples and patient DNA to explain why drugs do or don't work against certain cancers.


* MERGER OF GLAXO WELLCOME AND SMITHKLINE BEECHAM EXPECTED TO CLOSE THIS SUMMER.

** MERGER OF PFIZER AND WARNER-LAMBERT IS EXPECTED TO CLOSE EARLY JUNE.




_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

BACK TO TOP


RELATED ITEMS
The Genome Gold Rush

COVER IMAGE: Eureka! The Genome Gold Rush

TABLE: Unearthing DNA's Riches

The Genome Explained

What This Means to You

The Pharma Frenzy

TABLE: Genomics among the Giants

Survival of...Who?

CHART: The Biotech Roller Coaster

ONLINE ORIGINAL: William Haseltine on Human Genome Science's Plan

ONLINE ORIGINAL: The Slow, Painful Path to Payday in Genomic Stocks



INTERACT
E-Mail to Business Week Online

 
Copyright 2000-2009, Bloomberg L.P.
Terms of Use   Privacy Notice